Last updated: 11/04/2018 04:43:45
Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Clinical Evaluation of dutasteride in Benign Prostatic Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparative Study of GI198745 (dutasteride) in Subjects with Benign Prostatic Hyperplasia.
Trial description: This study will assess the efficacy and safety of GI198745 0.5mg given once daily for 52 weeks to Benign Prostatic Hyperplasia (BPH) patients.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Change from Baseline in International Prostate Symptom Score (IPSS) at Week 52
Timeframe: Baseline and Week 52
Secondary outcomes:
Percent Change from Baseline in Prostate Volume at Week 52
Timeframe: Baseline and Week 52
Number of Participants with IPSS Improvement from Baseline at Week 52
Timeframe: Baseline and Week 52
Change from Baseline in Maximum Urine Flow Rate (Qmax) at Week 52
Timeframe: Baseline and Week 52
Number of Participants with Qmax Improvement from Baseline at Week 52
Timeframe: Baseline and Week 52
Interventions:
Enrollment:
378
Primary completion date:
2007-06-12
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Tsukamoto T, Endo Y, Narita M; Efficacy and safety of dutasteride in Japanese men with benign prostatatic hyperplasia. Int J Urol. 2009 Sep.16(9).745-50
Tsukamoto T, Endo Y, Narita M; Efficacy and safety of dutasteride in Japanese men with benign prostatatic hyperplasia. Int J Urol. 2009 Sep.16(9).745-50
Medical condition
Prostatic Hyperplasia
Product
dutasteride
Collaborators
Not applicable
Study date(s)
February 2006 to December 2007
Type
Interventional
Phase
3
Participation criteria
Sex
Male
Age
50+ years
Accepts healthy volunteers
No
- Only subjects who meet all the following criteria during the screening phase will be enrolled in the study.
- 1.Diagnosis: BPH
- Patients who apply to any of the following criteria during the screening phase will not be enrolled in the study.
- 1.Post void residual volume >250mL (by suprapubic ultrasound).
Inclusion and exclusion criteria
Inclusion criteria:
- Only subjects who meet all the following criteria during the screening phase will be enrolled in the study. 1.Diagnosis: BPH 2.Age: ≥50 years 3.Gender: Male 4.Estimated prostate volume ≥30cc (by TRUS) 5.I-PSS Symptom Score (total of 7 items) ≥8 points 6.Maximum flow rate (Qmax) ≤15mL/sec (voided volume measured simultaneously ≤150mL)*[1] 7.Patients who meet either of the following regarding tamsulosin HCl use: Patients with tamsulosin HCl use: Patients who have received tamsulosin HCl continuously for at least 4 weeks and who are likely to continue to take tamsulosin HCl without any change to the dosage and administration of the drug until the end of study treatment. Patients without tamsulosin HCl use: Patients who haven't received tamsulosin HCl in the past 4 weeks and who are unlikely to use tamsulosin HCl until the end of study treatment. 8.Outpatients 9.Patients who in person have given written consent
Exclusion criteria:
- Patients who apply to any of the following criteria during the screening phase will not be enrolled in the study. 1.Post void residual volume >250mL (by suprapubic ultrasound). 2.History of AUR within the previous 12 weeks. 3.Evidence or history of prostate cancer. 4.PSA >10ng/mL [in patients with PSA >4ng/mL, the presence of prostate cancer should be ruled out by the investigator/subinvestigator. DRE and free/total PSA ratio should be considered, and prostate biopsy be conducted if necessary]. 5.Previous surgery (including balloon dilatation, thermotherapy and stent placement) or minimally invasive techniques for BPH. 6.Any causes other than BPH, which may in the judgment of the investigator/subinvestigator, affect evaluation of symptoms or urine flow (e.g., neurogenic bladder, bladder neck contracture, urethral stricture, bladder malignancy, acute/chronic prostatitis, acute/chronic urinary tract infection). 7.History of any unstable, serious co-existing medical condition(s) including, but not limited to, myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias*[2], congestive heart failure or cerebrovascular accident within the previous 6 months; or diabetes mellitus or peptic ulcer uncontrollable with medical treatment. 8.Liver function tests (AST, ALT, AL-P) >2 times the upper limit of normal. 9.Serum cleatinine >1.8mg/dL. 10.Use of any antiandrogen (e.g., chlormadinone acetate, allylesterenol) for BPH within the previous 12 months. 11.Use of a1-adrenoceptor blockers excluding tamsulosin HCl (e.g., prazosin HCl, urapidil slow-release capsule formulation, terazosin HCl, naftopidil), plant extract preparations for treatment of BPH (e.g., Eviprostat, cernitin pollen extract), herbal medicines (e.g., hachimi-jio-gan, gosha-jinki-gan), other drugs (e.g., Paraprost), and dietary or herbal supplements (e.g., saw palmetto) for relief of BPH symptoms within the previous 4 weeks. Use of a-adrenoceptor agonists (e.g., pseudoephedrine, phenyle *[1] Subjects with voided volume <150 mL at Qmax measurement cannot be enrolled in the study and may undergo re-measurement of Qmax before the visit for Week 0 for study entry. *[2] Of "Degree II" according to "Grading of Side Effects (PMSB Notification No. 80 dated June 29, 1992) or equivalent (Appendix 4).
Trial location(s)
Showing 1 - 6 of 26 Results
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2007-06-12
Actual study completion date
2007-06-12
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website